Press release
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present at Keystone Cancer Vaccines Conference
The talk titled "Therapeutic HPV16 Vaccination Is Effective as Monotherapy in Pre-Malignant Disease, but Requires Combination Treatment in HPV16-Induced Cancers" is scheduled for Thursday, January 24, 2019, at 17:00 as part of the session "Immune Monitoring of T Cells" (17:00-18-45, Pacific Ballroom).
The data will outline the T cell response to ISA Pharmaceuticals´ therapeutic vaccine ISA101 and the resulting clinical activity. ISA101 is directed against the HPV16 oncoproteins E6/E7 and is the Company´s clinical-stage lead compound. It is being developed to treat HPV16-induced cancers such as cervical cancer and head-and-neck cancer.
###
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP® lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with Cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. In addition, ISA develops SLP® immunotherapies to advance novel treatment options for orphan indications.
For more information, please visit www.isa-pharma.com.
SLP® and AMPLIVANT® are registered trademarks in Europe.
Miranda Molenaar
ISA Pharmaceuticals B.V.
J.H. Oortweg 19
NL-2333 CH Leiden
The Netherlands
T: +31 71 33 22 310
F: +31 71 33 22 311
E: info@isa-pharma.com
Contact & Media Inquiries:
akampion
Dr. Ludger Wess, Ines-Regina Buth
Managing Partners
Tel. +49 40 88 16 59 64, +49 30 23 63 27 68
info(at)akampion.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief to Present at Keystone Cancer Vaccines Conference here
News-ID: 1502313 • Views: …
More Releases from ISA Pharmaceuticals
ISA Pharmaceuticals to Present Phase 2 Cervical Cancer Data at AACR Annual Meeti …
- Results from Phase 2 cervical cancer trial with ISA101 selected for plenary oral presentation
Leiden, The Netherlands, March 28, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will give an oral presentation at the upcoming AACR Annual Meeting 2019 in Atlanta, GA, USA, on March 31, 2019.
The presentation titled "A strong HPV-specific T-cell response after chemo-immunotherapy for advanced…
ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Cornelis Melief Receiv …
- Recognition for outstanding and innovative cancer research
Leiden, The Netherlands, March 19, 2019 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Dr. Cornelis Melief will receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology 2019 from the American Association of Cancer Research (AACR) and the Cancer Research Institute.
The AACR-CRI Lloyd J. Old Award in Cancer Immunology recognizes an active…
ISA Pharmaceuticals Announces Start of Phase 2 Combination Trial of ISA101b and …
- ISA101b and Cemiplimab studied in patients with platinum refractory HPV16-positive oropharyngeal cancer (OPC)
Leiden, The Netherlands, January 21, 2019 – ISA Pharmaceuticals B.V., a clinical-stage company dedicated to the development of rationally designed immunotherapeutics, today announced randomization of the first patient in a Phase 2 combination trial of its lead compound ISA101b and Regeneron´s (NASDAQ: REGN) anti-PD-1 antibody cemiplimab (REGN2810).
This double blind, placebo-controlled, randomized, phase 2 study (NCT03669718)…
ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ES …
Leiden, The Netherlands, November 13, 2018 – ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief has been selected by the European Society for Medical Oncology (ESMO) to receive the 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer. He will receive the award during an official ceremony at the opening…
More Releases for HPV16
HPV16+ Cancer Pipeline Appears Robust With 10+ Key Pharma Companies Actively Wor …
DelveInsight's, "Human papillomavirus 16-positive (HPV16+) cancers Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Human papillomavirus 16-positive (HPV16+) cancers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest…
HPV16+ Anogenital Cancers Therapeutics Market Size in 7MM is expected to grow at …
DelveInsight's "HPV16+ Anogenital Cancers Market Insights, Epidemiology, and Market Forecast-2032" Report delivers an in-depth understanding of the HPV16+ Anogenital Cancers, historical and forecasted epidemiology as well as the HPV16+ Anogenital Cancers market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover which therapies are expected to grab the HPV16+ Anogenital Cancers Market Share @ HPV16+ Anogenital Cancers Market Outlook- https://www.delveinsight.com/sample-request/hpv16-anogenital-cancers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the…
HPV16+ Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Asse …
HPV16+ Cancer Pipeline constitutes 10+ key companies continuously working towards developing 12+ HPV16+ Cancer treatment therapies, analyzes DelveInsight.
HPV16+ Cancer Overview:
Human papillomavirus 16 (HPV16) is a high-risk strain of HPV strongly associated with various cancers, including cervical, oropharyngeal cancers. As a DNA virus, HPV16 infects epithelial cells and is primarily transmitted through sexual contact. Persistent HPV16 infection significantly increases the risk of developing malignant tumors, making it a critical public health…
HPV16+ Cancer Market Potential: Analyzing Market Growth Trends and Growth Opport …
DelveInsight's "HPV16+ Cancer Patient Pool Analysis, Market Size and Market Forecast APAC - 2034″ report offers an in-depth understanding of the HPV16+ Cancer, historical and forecasted epidemiology as well as the HPV16+ Cancer market trends in the APAC region (India, China, South Korea, Taiwan, and Australia).
To Know in detail about the HPV16+ Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; HPV16+ Cancer Market Forecast
https://www.delveinsight.com/sample-request/hpv16-positive-cancer-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some…
Human Papillomavirus 16-positive (HPV16+) Cancers Pipeline Analysis (2023) Cover …
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Human Papillomavirus 16-positive (HPV16+) Cancers therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Human Papillomavirus 16-positive…
HPV16+Anogenital Cance Market is Expected to Show a Healthy Growth Rate During t …
(Las Vegas, Nevada, United States) "DelveInsight's "HPV16+Anogenital Cancer market Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the HPV16+Anogenital Cancer market, historical and forecasted epidemiology as well as the HPV16+Anogenital Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
Download Sample Report to know more @https://www.delveinsight.com/sample-request/hpv16-anogenital-cancers-market?utm_source=benzinga&utm_medium=pressrelease&utm_campaign=dpr
HPV16+Anogenital Cancer Overview
Human papillomavirus infection (HPV infection) is caused by a DNA virus…
